• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迈向特应性皮炎研究结局指标的全球共识:HOME II 会议的结果。

Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.

机构信息

Centre for Evidence-Based Healthcare, University Hospital Dresden, Germany.

出版信息

Allergy. 2012 Sep;67(9):1111-7. doi: 10.1111/j.1398-9995.2012.02874.x. Epub 2012 Jul 30.

DOI:10.1111/j.1398-9995.2012.02874.x
PMID:22844983
Abstract

The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.

摘要

在特应性皮炎临床试验中使用非标准化和验证不足的结局测量方法是实践循证皮肤病学的主要障碍。特应性皮炎结局测量协调(HOME)倡议是一个国际多专业小组,致力于特应性皮炎结局研究。2011 年 6 月,HOME 倡议进行了一项共识研究,涉及来自 10 个国家的 43 名代表,代表不同的利益相关者(患者、临床医生、方法学家、制药行业),以确定特应性皮炎临床试验的核心结局领域,定义特应性皮炎结局测量的质量标准,并为特应性皮炎结局研究确定优先事项。代表们收到了基于证据的信息,然后进行了结构化的小组讨论和匿名共识投票。达成共识,将临床体征、症状、发作的长期控制和生活质量纳入特应性皮炎临床试验的核心结局领域。HOME 倡议强烈建议将这些核心结局领域作为特应性皮炎临床试验的主要或次要终点进行包括和报告。这些核心结局领域的测量方法需要具有有效性、对变化敏感和可行性。HOME 倡议的优先事项是确定/开发适用于四个核心结局领域的最适当工具。HOME 向所有对特应性皮炎结局研究感兴趣的人开放。

相似文献

1
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.迈向特应性皮炎研究结局指标的全球共识:HOME II 会议的结果。
Allergy. 2012 Sep;67(9):1111-7. doi: 10.1111/j.1398-9995.2012.02874.x. Epub 2012 Jul 30.
2
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.特应性皮炎临床试验中与健康相关的生活质量、长期控制和瘙痒强度的推荐核心结局指标:HOME VII 共识会议的结果。
Br J Dermatol. 2021 Jul;185(1):139-146. doi: 10.1111/bjd.19751. Epub 2021 Feb 8.
3
The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.特应性皮炎临床试验中评估临床体征的湿疹结局指标(HOME)声明。
J Allergy Clin Immunol. 2014 Oct;134(4):800-7. doi: 10.1016/j.jaci.2014.07.043.
4
Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.特应性皮炎临床试验中实施 HOME 核心结局集的障碍和机遇:HOMEIX 会议报告。
Arch Dermatol Res. 2023 Nov;315(9):2617-2622. doi: 10.1007/s00403-023-02647-w. Epub 2023 Jul 11.
5
Reaching clinically relevant outcome measures for new pharmacotherapy and immunotherapy of atopic eczema.为特应性皮炎的新药物疗法和免疫疗法达成具有临床相关性的疗效指标。
Curr Opin Allergy Clin Immunol. 2015 Jun;15(3):227-33. doi: 10.1097/ACI.0000000000000158.
6
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).特应性皮炎临床试验协调核心结局指标的第四次国际共识会议报告(HOME 倡议)。
Br J Dermatol. 2016 Jul;175(1):69-79. doi: 10.1111/bjd.14773. Epub 2016 Jul 19.
7
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.特应性皮炎试验中与健康相关的生活质量、长期控制和瘙痒强度的推荐核心结局指标:HOME VII共识会议结果
Br J Dermatol. 2020 Nov 11. doi: 10.1111/bjd.19673.
8
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).特应性皮炎临床试验协调核心结局指标的第五次国际共识会议报告(HOME 倡议)。
Br J Dermatol. 2018 May;178(5):e332-e341. doi: 10.1111/bjd.16543. Epub 2018 Apr 19.
9
Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.在临床实践中测量特应性皮炎症状:来自特应性皮炎临床实践中协调结局测量倡议的第一份共识声明。
J Am Acad Dermatol. 2020 May;82(5):1181-1186. doi: 10.1016/j.jaad.2019.12.055. Epub 2020 Jan 8.
10
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.临床实践中特应性皮炎控制情况及瘙痒强度的测量:临床实践中湿疹统一结局测量(HOME-CP)倡议的共识声明
JAMA Dermatol. 2022 Dec 1;158(12):1429-1435. doi: 10.1001/jamadermatol.2022.4211.

引用本文的文献

1
Assessing Atopic Dermatitis Control in Chinese Patients: Validation of the Chinese Version of Recap of Atopic Eczema Questionnaire (RECAP) and an Investigation into Its Interpretability.评估中国患者特应性皮炎的控制情况:特应性湿疹问卷摘要(RECAP)中文版的验证及其可解释性调查。
Acta Derm Venereol. 2025 Jul 8;105:adv43458. doi: 10.2340/actadv.v105.43458.
2
Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of life.手部湿疹试验核心领域的共识:体征、症状、控制及生活质量。
J Eur Acad Dermatol Venereol. 2025 Sep;39(9):1588-1599. doi: 10.1111/jdv.20671. Epub 2025 Apr 25.
3
The Atopic Dermatitis Control Tool: Adaptation and Content Validation for Children and Caregivers of Children with Atopic Dermatitis.
特应性皮炎控制工具:针对特应性皮炎患儿及其照料者的改编与内容效度验证
Dermatol Ther (Heidelb). 2024 Dec;14(12):3261-3271. doi: 10.1007/s13555-024-01289-8. Epub 2024 Nov 21.
4
Topical anti-inflammatory treatments for eczema: network meta-analysis.外用抗炎治疗湿疹:网状荟萃分析。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015064. doi: 10.1002/14651858.CD015064.pub2.
5
Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting.亚洲临床环境中用于评估成人患者湿疹控制情况的 RECAP(特应性皮炎总结评估)测量工具的验证。
Acta Derm Venereol. 2024 May 13;104:adv32323. doi: 10.2340/actadv.v104.32323.
6
Defining and Measuring the Scope of Atopic Dermatitis.定义和测量特应性皮炎的范围。
Adv Exp Med Biol. 2024;1447:105-116. doi: 10.1007/978-3-031-54513-9_10.
7
Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT.洗剂、乳膏、凝胶和软膏治疗儿童湿疹的比较:BEE RCT。
Health Technol Assess. 2023 Oct;27(19):1-120. doi: 10.3310/GZQW6681.
8
Implementation of the HOME core outcome set for clinical trials of atopic eczema-barriers and opportunities: the HOME IX meeting report.特应性皮炎临床试验中实施 HOME 核心结局集的障碍和机遇:HOMEIX 会议报告。
Arch Dermatol Res. 2023 Nov;315(9):2617-2622. doi: 10.1007/s00403-023-02647-w. Epub 2023 Jul 11.
9
Core outcome sets in medical research.医学研究中的核心结局集
BMJ Med. 2022 Oct 17;1(1):e000284. doi: 10.1136/bmjmed-2022-000284. eCollection 2022.
10
Atopic Dermatitis: Clinical Aspects and Unmet Needs.特应性皮炎:临床方面及未满足的需求
Biomedicines. 2022 Nov 14;10(11):2927. doi: 10.3390/biomedicines10112927.